1-4 of 4
Claire Hutchinson
Close
Sort by
Journal Articles

The Impact of Pausing Bruton Tyrosine Kinase Inhibitor Therapy and Responsiveness of Vaccination in Blood Cancer Patients: Primary Outcome Result for the Randomised Improve Trial

Piers Patten, Jonathan Cook, Nicholas Peckham, Paul Moss, Neil Phillips, Abhishek Abhishek, Thomas Roberts, Georgina Talbot, Vicki Barber, Anne Francis, Fiona Ashford, Lelia Duley, Robbert Hoogeboom, Brian Willett, Nilima Parry-Jones, Toby A. Eyre, Farooq Ahmad Wandroo, Claire Hutchinson, Duncan James Murray, Gratian Vandici, Nicolas Martinez-Calle, Stephen Jenkins, Helen M Parry
Journal: Blood
Blood (2023) 142 (Supplement 1): 1904.
https://doi.org/10.1182/blood-2023-188725
Published: 2023
Journal Articles

The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)

Christopher Fegan, Joanne Bagshawe, Gilles Salles, MDPhD, Lionel Karlin, Simon Rule, Nimish Shah, Franck Morschhauser, Louis Terriou, Martin JS Dyer, Harriet Walter, Claire Hutchinson, Guillaume Cartron, MD, John Sharpe, Kevin Duffy, Akhisa Nishimura, Shin-ichiro Abe, Hideyuki Honda, Tomoko Yasuhiro, Toshio Yoshizawa, Joseph Birkett, Nigel Courtenay-Luck
Journal: Blood
Blood (2014) 124 (21): 3328.
https://doi.org/10.1182/blood.V124.21.3328.3328
Published: 2014
Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Simon Rule, MD, Nimish Shah, MD, Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, James G Wright, PhD, Andrew J Saunders, MD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD
Journal: Blood
Blood (2013) 122 (21): 4397.
https://doi.org/10.1182/blood.V122.21.4397.4397
Published: 2013
Journal Articles

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Gilles Andre Salles, MD, PhD, Lionel Karlin, MD, Simon Rule, MD, Nimish Shah, MD, Franck Morschhauser, MD, PhD, Louis Terriou, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Claire Hutchinson, BMedSci, MRCP, FRCPath, Chris Fegan, MBBS, Guillaume Cartron, MD, PhD, Tomasz Knurowski, MD, Andrew J Saunders, MD, James G Wright, PhD, Hideyuki Honda, Bsc, Andrew Mazur, Toshio Yoshizawa, PhD, Kazuhito Kawabata, PhD, Joseph TP Birkett, PhD
Journal: Blood
Blood (2013) 122 (21): 676.
https://doi.org/10.1182/blood.V122.21.676.676
Published: 2013